Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/1999

01-11-1999 | ORIGINAL ARTICLE

Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009

Authors: Randall F. Holcombe, Joth Jacobson, Shaker R. Dakhil, Ruby M. Stewart, Kenneth S. Betzing, Krishna Kannan, John S. Macdonald

Published in: Cancer Immunology, Immunotherapy | Issue 9/1999

Login to get access
Metadata
Title
Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009
Authors
Randall F. Holcombe
Joth Jacobson
Shaker R. Dakhil
Ruby M. Stewart
Kenneth S. Betzing
Krishna Kannan
John S. Macdonald
Publication date
01-11-1999
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/1999
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s002620050602

Other articles of this Issue 9/1999

Cancer Immunology, Immunotherapy 9/1999 Go to the issue

ORIGINAL ARTICLE

Sialoadhesin expression by bone marrow macrophages derived from Ehrlich-tumor-bearing mice

ORIGINAL ARTICLE

The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells

ORIGINAL ARTICLE

Sensitization of resting T cells to autologous natural-killer-cell-mediated lysis by phytohemagglutinin

ORIGINAL ARTICLE

Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells

ORIGINAL ARTICLE

Modulation of CD4 cell cytokine production by colon cancer-associated mucin

ORIGINAL ARTICLE

Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits